MX2017000676A - Oritavancina de alta pureza y metodo para producir la misma. - Google Patents

Oritavancina de alta pureza y metodo para producir la misma.

Info

Publication number
MX2017000676A
MX2017000676A MX2017000676A MX2017000676A MX2017000676A MX 2017000676 A MX2017000676 A MX 2017000676A MX 2017000676 A MX2017000676 A MX 2017000676A MX 2017000676 A MX2017000676 A MX 2017000676A MX 2017000676 A MX2017000676 A MX 2017000676A
Authority
MX
Mexico
Prior art keywords
high purity
oritavancin
producing same
purity oritavancin
pharmaceutical compositions
Prior art date
Application number
MX2017000676A
Other languages
English (en)
Inventor
Rafai Far Adel
Krishna Gopal
Ding Min
R Chemburkar Sanjay
M Knable Carl
J Pruyne Julie
M Reamer Douglas
P Petzel James
Original Assignee
The Medicines Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Medicines Co filed Critical The Medicines Co
Publication of MX2017000676A publication Critical patent/MX2017000676A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/006—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure
    • C07K9/008—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure directly attached to a hetero atom of the saccharide radical, e.g. actaplanin, avoparcin, ristomycin, vancomycin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Se describen preparaciones de sustancia fármaco de oritavacina que tienen alta pureza, junto con composiciones farmacéuticas que comprenden tales preparaciones de sustancia fármaco de oritavacina, y productos de fármaco o formas de dosificación que comprenden tales composiciones farmacéuticas.
MX2017000676A 2014-07-17 2015-07-16 Oritavancina de alta pureza y metodo para producir la misma. MX2017000676A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462025737P 2014-07-17 2014-07-17
PCT/US2015/040736 WO2016011245A1 (en) 2014-07-17 2015-07-16 High purity oritavancin and method of producing same

Publications (1)

Publication Number Publication Date
MX2017000676A true MX2017000676A (es) 2018-01-11

Family

ID=55073658

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017000676A MX2017000676A (es) 2014-07-17 2015-07-16 Oritavancina de alta pureza y metodo para producir la misma.

Country Status (12)

Country Link
US (3) US9649352B2 (es)
EP (1) EP3169345A4 (es)
JP (1) JP6712991B2 (es)
CN (1) CN107206050A (es)
AU (1) AU2015289602B2 (es)
BR (1) BR112017000898A2 (es)
CA (1) CA2955256C (es)
EA (1) EA201700019A1 (es)
HK (1) HK1244447A1 (es)
MX (1) MX2017000676A (es)
NZ (1) NZ728401A (es)
WO (1) WO2016011245A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107793472A (zh) * 2016-09-07 2018-03-13 浙江海正药业股份有限公司 奥利万星二磷酸盐的晶型及其制备方法和用途
CN106928323B (zh) * 2017-03-02 2021-08-20 重庆乾泰生物医药有限公司 一种高纯度奥利万星关键中间体a82846b的制备方法
CN109053864B (zh) * 2018-07-10 2021-08-24 丽珠集团新北江制药股份有限公司 一种制备奥利万星的方法
CN109053865B (zh) * 2018-07-20 2021-04-13 丽珠集团新北江制药股份有限公司 一种羧基保护制备奥利万星的方法
CN109762860B (zh) * 2019-04-02 2021-10-01 博瑞生物医药泰兴市有限公司 一种碱降解液
CN109811023B (zh) * 2019-04-02 2021-08-06 博瑞生物医药泰兴市有限公司 A82846b的发酵制备方法
CN109811024B (zh) * 2019-04-02 2021-08-06 博瑞生物医药泰兴市有限公司 发酵制备奥利万星中间体的方法
CN110824079B (zh) * 2019-11-27 2021-04-13 苏州赛分科技有限公司 特拉万星的纯化方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EG18377A (en) 1986-09-19 1993-04-30 Lilly Co Eli Process for preparing glycopeptide antibiotics
US4845194A (en) 1987-02-27 1989-07-04 Eli Lilly And Company Glycopeptide recovery process
IL96603A (en) * 1989-12-13 1998-02-08 Lilly Co Eli Antibacterial glycopeptide derivativesProcess for their preparation and pharmaceutical preparations containing the same
US5840684A (en) * 1994-01-28 1998-11-24 Eli Lilly And Company Glycopeptide antibiotic derivatives
MY128335A (en) * 1994-01-28 2007-01-31 Lilly Co Eli Glycopeptide antibiotic derivatives
ID18900A (id) * 1996-11-21 1998-05-20 Lilly Co Eli Alkilasi menurun dari gliko peptida anti biotik
US5952466A (en) 1997-11-12 1999-09-14 Eli Lilly And Company Reductive alkylation of glycopeptide antibiotics
US5939382A (en) 1996-11-21 1999-08-17 Eli Lilly And Company Reducing agent for reductive alkylation of glycopeptide antibiotics
ATE267209T1 (de) 1998-05-05 2004-06-15 Lilly Co Eli Reinigung von carboxaldehyd
US6696412B1 (en) * 2000-01-20 2004-02-24 Cubist Pharmaceuticals, Inc. High purity lipopeptides, Lipopeptide micelles and processes for preparing same
US7119061B2 (en) 2002-11-18 2006-10-10 Vicuron Pharmaceuticals, Inc. Dalbavancin compositions for treatment of bacterial infections
DK1565201T3 (en) 2002-11-18 2019-02-25 Vicuron Pharmaceuticals Llc METHODS OF ADMINISTRATING DALBAVANCIN TO TREAT Bacterial Infections
ES2884673T3 (es) 2008-04-08 2021-12-10 Melinta Therapeutics Inc Oritavancina para inhibir y tratar biopelículas
CN102215858A (zh) * 2008-08-30 2011-10-12 塔尔甘塔治疗公司 使用单剂量奥利万星的治疗方法
US9682061B2 (en) 2009-04-28 2017-06-20 The Medicines Company Methods of treating bacterial infections using oritavancin
WO2011019839A2 (en) * 2009-08-12 2011-02-17 The Medicines Company Glycopeptide and lipoglycopeptide antibiotics with improved solubility

Also Published As

Publication number Publication date
EP3169345A4 (en) 2018-01-17
US20170157206A1 (en) 2017-06-08
CN107206050A (zh) 2017-09-26
US9649352B2 (en) 2017-05-16
HK1244447A1 (zh) 2018-08-10
US20160015772A1 (en) 2016-01-21
US10864249B2 (en) 2020-12-15
EA201700019A1 (ru) 2017-07-31
NZ728401A (en) 2020-08-28
US10328118B2 (en) 2019-06-25
JP2017521443A (ja) 2017-08-03
JP6712991B2 (ja) 2020-06-24
BR112017000898A2 (pt) 2017-11-21
AU2015289602B2 (en) 2020-06-25
US20190290723A1 (en) 2019-09-26
WO2016011245A1 (en) 2016-01-21
CA2955256C (en) 2023-02-14
CA2955256A1 (en) 2016-01-21
AU2015289602A1 (en) 2017-02-09
EP3169345A1 (en) 2017-05-24

Similar Documents

Publication Publication Date Title
ZA201802657B (en) Crystal forms of beta-nicotinamide mononucleotide
IL269444B (en) New modified indazoles, methods for their production, pharmaceutical preparations containing the new modified indazoles, and the use of the new modified indazoles in the production of drugs
AU2018256640A1 (en) Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
NZ728401A (en) High purity oritavancin and method of producing same
EP3349762A4 (en) CO-CRYSTALS OF SGLT2 INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THEREOF
EP3357491A4 (en) PHARMACEUTICAL COMPOSITION WITH ANIONIC ACTIVE SUBSTANCE AND MANUFACTURING METHOD THEREFOR
PH12017500239A1 (en) Abiraterone acetate formulation and methods of use
IL254747A0 (en) History of benzaimidazolyl, their preparation and pharmaceutical preparations containing them
IL272168A (en) The compositions for increasing the bioavailability of drugs, additives and substances for ingestion
MX2018002318A (es) Proceso mejorado para producir fucoxantina y/o polisacaridos de microalgas.
EP3093023A4 (en) Pharmaceutical composition for cancer treatment and pharmaceutical preparation for cancer treatment containing same composition as active ingredient
EP3168214A4 (en) Substituted 2-thioxo-imidazolidin-4-ones and spiro analogues thereof, active anti-cancer ingredient, pharmaceutical composition, medicinal preparation, method for treating prostate cancer
EP3560518A4 (en) COMPLEX FOR ADMINISTRATION AND STABILIZATION OF MEDICINAL PRODUCTS AND METHOD FOR MANUFACTURING THEREOF
MX2017014456A (es) Usos terapeuticos de l-4-cloroquinurenina.
IN2014CH00840A (es)
AU2015303724B2 (en) Quinazoline derivative
IL258977B (en) Pyperidyl derivatives, their preparation and pharmaceutical compositions containing them
EP3378493A4 (en) NOVEL NANOPREPARATION OF ANTICANCER DRUG AND PREPARATION METHOD THEREOF
EP3398608A4 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF CANCER OR CANCER METASTASES WITH PSTL1-PRTEIN AS AN ACTIVE SUBSTANCE
EP3275864A4 (en) Compound of 3-hydroxyl pyridine, preparation method thereof and pharmaceutical use thereof
EP3727367A4 (en) VITAMIN K2 COMPOSITIONS FOR THE TREATMENT OF DRUG-INDUCED NEUROPATHY